"MD Anderson Madrid es en la actualidad centro de referencia y de excelencia para el tratamiento del cáncer en España y en Europa gracias a un equipo de profesionales altamente especializados, a las magníficas instalaciones actuales y a la continua y estrecha colaboración con MD Anderson Cancer Center de Houston. Además, MD Anderson Madrid cuenta entre sus profesionales con equipos de investigación de talla internacional lo que nos permite ofrecer a nuestros pacientes los últimos avances en el tratamiento y diagnóstico del cáncer."

During the past decade, MD Anderson Cancer Centre Madrid conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MD Anderson Cancer Centre Madrid" #1 sponsor was "Incyte Corporation" with 2 trials, followed by "Centro Nacional de Investigaciones Oncologicas CARLOS III" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored, "Gynecologic Oncology Group" with 1 trials sponsored and "National Cancer Institute (NCI)" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MD Anderson Cancer Centre Madrid" #1 collaborator was "Grupo Espanol de Investigacion del Cancer de Mama" with 1 trials as a collaborator, "Hospital Universitari de Bellvitge" with 1 trials as a collaborator, "Hospital Universitario de Fuenlabrada" with 1 trials as a collaborator, "M.D. Anderson Cancer Center" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "MD Anderson Cancer Centre Madrid" are "Cervical Adenocarcinoma" (2 trials), "Cervical Adenosquamous Carcinoma" (2 trials), "Cervical Squamous Cell Carcinoma" (2 trials), "Lymphoma" (2 trials) and "Recurrent Cervical Carcinoma" (2 trials). Many other conditions were trialed in "MD Anderson Cancer Centre Madrid" in a lesser frequency.

Most popular intervention types in "MD Anderson Cancer Centre Madrid" are "Drug" (5 trials), "Biological" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Parsaclisib" (2 trials), "BIBF + Paclitaxel" (1 trials), "Bevacizumab" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "MD Anderson Cancer Centre Madrid" are 3 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "MD Anderson Cancer Centre Madrid". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in MD Anderson Cancer Centre Madrid, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MD Anderson Cancer Centre Madrid, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".